Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of GIA632 in adults with non-segmental vitiligo
CTR20261246Phase 2Active
- Sponsor
- Novartis
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GIA632 in Vitiligo, sponsored by Novartis. Started Jun 2026; status: active.
02
Drugs
GIA632
03
Conditions
Vitiligo
Beyond the preview
Go deeper on CTR20261246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261246.